Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19

Abstract

The article evaluates the results of Riamilovir use in treatment of patients with a moderate form of the disease caused by a new strain of the SARS-CoV-2 virus. It was found that the average time required to complete resolution of symptoms during treatment with the drug was 6-7 days. The first negative result of PCR analysis for the SARS-CoV-2 virus was registered on the 10-11th day of therapy; two consecutive negative PCR results for the SARS-CoV-2 virus were registered in the majority of patients by day 14–19 of treatment in 63±4.28%. The body temperature of the majority of patients (75%) returned to normal by the 4th day of treatment. CT scan showed improvement in the lungs of patients: a repeated CT scan performed on average on day 19 from the start of therapy showed no lung damage or no progression in 10±3.0% of patients following therapy. The CT scan of the lungs performed in 1-2 months after the treatment showed that the number of patients with no lung damage increased to 27±4.44%. As a result of treatment, a decrease in the C-reactive protein index was observed in patients. The tolerability level of the drug was assessed as good: no adverse events or significant deviations in laboratory parameters were detected.

Pyrimido[1,2-a]benzimidazoles: synthesis and perspective of their pharmacological use

“…11,12 Triazavirin has been shown to be effective in treating patients with moderate COVID-19. 13,14 Antiviral medication 5-methyl-6-nitro-7-oxo-4,7-dihydro [1,2,4]triazolo [1,5-a]pyrimidine L-arginine salt monohydrate is at the stage of clinical trials. 15,16 At the same time, this is not the only method of constructing the important heterocyclic structures with relevant biological activity.…”

Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19)

“…Важно отметить, что данный препарат уже имеет опыт применения на базе российских и зарубежных ковидных госпиталей в качестве этиотропного средства при терапии коронавирусной инфекции как в составе комбинированных схем лечения, так и монотерапии [7][8][9].…”

Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir (“Triazavirin®”) active against SARS-CoV-2 (COVID-19)

“…Moreover, there is a successful experience of using Riamilovir in COVID hospitals as an etiotropic agent in the treatment of coronavirus infection SARS-CoV-2 (COVID- 19), and also for the prevention of this disease. [6][7][8][9][10][11][12][13][14] Thus, the development of convenient methods for the synthesis of azolo [1,2,4]triazines, in particular, derivatives of 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-one, is extremely important, especially in terms of the development of atom-economical approaches that correspond to the principles of green chemistry, for the preparation of new drugs and drug candidates. Previously, several review articles were published on the synthesis of various azolo [1,2,4]triazines and their biological activities.…”